HealthcareServices

Deep Learning In Drug Discovery And Diagnostics Industry Growth Insights: Revenue Forecast to 2030

February 23, 2026February 24, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the deep learning in drug discovery and diagnostics market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Deep Learning In Drug Discovery And Diagnostics Market?

The deep learning in drug discovery and diagnostics market size has seen substantial expansion in recent years. This market is projected to expand from $10.58 billion in 2025 to $13.61 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 28.7%. Historically, this growth can be attributed to several factors such as the increasing availability of large biomedical datasets, rising computational power for model training, the expansion of AI adoption in pharmaceutical R&D, a growing demand for faster drug discovery cycles, and the early success of deep learning diagnostic models.

The market for deep learning in drug discovery and diagnostics is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $36.96 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 28.4%. Factors contributing to this growth during the forecast period include greater financial commitments to AI-driven healthcare solutions, a surging need for precision medicine, broader integration of AI into clinical processes, wider utilization of real-world evidence data, and increasing regulatory approval for AI-supported diagnostics. Key trends expected over the forecast period encompass the growing incorporation of deep neural networks into drug screening, the escalating application of AI-powered predictive modeling in diagnostics, enhanced integration of multi-omics data analysis, the proliferation of automated clinical decision support systems, and a heightened emphasis on platforms for personalized medicine.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19394&type=smp

What Drivers Are Supporting Technological Adoption In The Deep Learning In Drug Discovery And Diagnostics Market?

The expanding need for personalized medicine is projected to stimulate the growth of the deep learning in drug discovery and diagnostics market in the coming period. This approach involves customizing medical treatments and interventions for individuals based on their unique genetic, environmental, and lifestyle characteristics, aiming to enhance effectiveness and reduce adverse reactions. The increasing requirement for personalized medicine stems from progress in genomics and data analytics, allowing for more accurate and potent therapies designed around specific patient profiles. Within drug discovery and diagnostics, deep learning improves personalized medicine by examining intricate biological data to pinpoint distinct biomarkers and forecast how patients will respond to treatments with greater precision. As an illustration, in February 2024, data from the Personalized Medicine Coalition, a US-based non-profit entity, showed that the FDA granted approval to 16 new personalized therapies for individuals with rare diseases in 2023, an increase from six in 2022. Consequently, the rising demand for personalized medicine is a key driver for the deep learning in drug discovery and diagnostics market.

What Segment Types Are Examined In The Deep Learning In Drug Discovery And Diagnostics Market?

The deep learning in drug discovery and diagnostics market covered in this report is segmented –

1) By Type: Drug Discovery, Diagnostics, Forensic Interventions, Other Types

2) By Drug Type: Small Molecule Drugs, Biologics Drugs

3) By End Use Industry: Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs), Healthcare Information Technology (IT)

Subsegments:

1) By Drug Discovery: Target Identification, Drug Screening, Lead Optimization, Predictive Modeling

2) By Diagnostics: Medical Imaging Analysis, Genomic Data Interpretation, Disease Detection Algorithms, Personalized Medicine

3) By Forensic Interventions: Digital Pathology, Forensic DNA Analysis, Toxicology Screening, Crime Scene Reconstruction

4) By Other Types: Biomarker Discovery, Predictive Analytics in Healthcare, Patient Data Management Systems

What Upcoming Trends Are Likely To Define The Future Path Of The Deep Learning In Drug Discovery And Diagnostics Market?

Key companies operating within the deep learning in drug discovery and diagnostics market are integrating advanced technologies, such as generative artificial intelligence (AI) and machine-learning (ML)–driven automation platforms. This strategy aims to enhance efficiency, reduce research and development (R&D) costs, and accelerate the initial stages of therapeutic discovery. Generative AI and ML-driven automation platforms represent computational systems that learn from chemical and biological data to digitally design new drug candidates, predict molecular behavior, and automatically synthesize and test compounds using robotic systems, thereby decreasing dependence on traditional high-throughput screening. For instance, in July 2024, Exscientia, a UK-based AI-driven drug-design company, introduced its AWS-powered AI/ML platform. This platform integrates a “DesignStudio” for AI-based molecule generation with an “AutomationStudio” for robotic lab synthesis and testing. Operating in a closed “design–make–test–learn” loop, the platform continuously refines its AI models with experimental data, significantly speeding up discovery, improving scalability, and enabling the more precise and cost-effective development of novel therapeutics.

Who Are The Top-Performing Companies In The Deep Learning In Drug Discovery And Diagnostics Market In Recent Years?

Major companies operating in the deep learning in drug discovery and diagnostics market are Google Inc., Microsoft Corporation, International Business Machines Corporation, NVIDIA Corporation, Zebra Medical Vision Ltd, Tempus Labs Inc., Nanostring Technologies Inc., Owkin Inc., Insilico Medicine Inc., SOPHiA GENETICS SA, Qureai Technologies Pvt Ltd, H2Oai Inc., Arterys Inc., Deep Genomics Inc., GNS Healthcare Inc., MedAware Systems Inc., PathAI Inc., Kheiron Medical Technologies Ltd, CureMetrix Inc., OncoImmunity AS, Proscia Inc., BenevolentAI Ltd, BioXcel Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/deep-learning-in-drug-discovery-and-diagnostics-global-market-report

Which Region Currently Holds The Largest Share Of The Deep Learning In Drug Discovery And Diagnostics Market?

North America was the largest region in the deep learning in drug discovery and diagnostics market in 2025. The regions covered in the deep learning in drug discovery and diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Deep Learning In Drug Discovery And Diagnostics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19394&type=smp

Browse Through More Reports Similar to the Global Deep Learning In Drug Discovery And Diagnostics Market 2026, By The Business Research Company

Drug Discovery Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/drug-discovery-services-global-market-report

Artificial Intelligence In Drug Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-drug-discovery-global-market-report

Drug Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/drug-discovery-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795